Biotech Startups

Macromoltek provides computational modeling and AI-driven antibody design services to biotech and pharmaceutical companies, accelerating the discovery and optimization of therapeutic antibodies. The platform reduces time-to-market and increases the probability of clinical success in drug development.

1 investor

Maculaser develops a temperature-controlled retinal laser therapy to treat age-related macular degeneration, diabetic macular edema, and other retinal disorders by activating natural healing responses in eye cells. The company targets patients and healthcare providers globally for disease prevention and non-invasive retinal care.

1 investor

1 investor

MAG-LAB provides NMR spectroscopy services combined with selective protein isotope labeling techniques to analyze protein-ligand interactions at atomic resolution for drug discovery. It supports pharmaceutical and medicinal chemistry teams in hit finding, hit-to-lead optimization, binding site mapping, and characterizing challenging targets including intrinsically disordered proteins.

1 investor

Magmatic designs and builds custom synthetic proteins that selectively bind and separate metals from complex mixtures, using an AI-powered bioengineering platform. Its biorefining process targets critical minerals such as lithium, rare earth elements, nickel, and manganese, serving the critical minerals supply chain and material recycling from batteries and electronic waste.

1 investor

Magnendo develops a magnetically steerable soft-robotic guidewire system for neurovascular endovascular procedures, enabling physicians to access hard-to-reach targets in the brain's blood vessels for stroke and aneurysm treatment. The system is designed to reduce procedural time, complications, and costs while improving patient outcomes.

1 investor

1 investor

1 investor

Magnus Medical develops SAINT, an FDA-cleared, accelerated form of TMS (transcranial magnetic stimulation) therapy that uses precision neuromodulation to treat Major Depressive Disorder, including treatment-resistant depression, over a 5-day course. The noninvasive, non-drug treatment was developed at Stanford's Brain Stimulation Lab and is delivered to patients through verified clinical providers.

1 investor

A company using artificial intelligence to identify natural proteins of interest, operating at the intersection of foodtech, immunology, and biotech.

1 investor

MAIA Biotech is a clinical-stage biopharmaceutical company developing telomere-targeting cancer therapies, with a lead compound (THIO) based on a telomerase-targeting therapeutic approach. Its work spans oncology and nucleic acid-based therapeutics across multiple tumor types.

1 investor

Maman develops a microneedle-based medical device that replaces repeated self-injections and offers real-time hormonal monitoring using proprietary drug delivery technology. The company targets patients requiring frequent injections.

1 investor

Manna Molecular develops cannabis and CBD products using scientific methods, creating transdermal patches, serums, lotions, and delivery systems for precise dosing and personalized therapy.

1 investor

MantaBio builds an automated contamination and sterility testing platform for the drug supply chain, using a closed single-cartridge automated vPCR workflow (the MantaVision Automated vPCR Platform) for release and in-process microbial detection. It serves biopharma manufacturers, CDMOs, and clinical sites, deployable from the bioreactor floor to point-of-care manufacturing sites.

1 investor

MapLight develops neurological and neuropsychiatric drug therapies using a discovery platform that identifies neural circuits linked to disease for targeted treatment of conditions like schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder.

1 investor

MARAbio is a precision immunology company developing blood tests to identify Maternal Autoantibody Related Autism (MARA), a subtype estimated to represent up to 20% of autism diagnoses, alongside companion diagnostics and therapeutic antibody interventions for early detection and targeted treatment.

1 investor

1 investor

Maracorp produces fish-free Omega-3 supplements derived from algae for human health and nutrition. The company focuses on sustainable, plant-based alternatives to fish oil for consumer wellness.

1 investor

Marco transforms discarded coffee grounds from Parisian offices into cosmetic ingredients and biomaterials using supercritical CO2 extraction and green chemistry processes. The company produces natural cosmetic actives (OILCO, BUTTERCO, MARCO) with complete supply chain traceability and reduced carbon footprint.

1 investor

Marengo Therapeutics is a clinical-stage biotech company developing TCR-targeting antibodies that activate specific T cell subsets by targeting Variable β (Vβ) chain variants of the T cell receptor. Its approach aims to modulate the immune system to treat cancer and other diseases.

1 investor

1 investor

Marksans Pharma is an Indian pharmaceutical company that researches, manufactures, and markets finished dosage pharmaceutical formulations. Its portfolio spans over-the-counter consumer self-care products and prescription (Rx) therapeutic segments, sold across global markets.

1 investor

Martínez Nieto manufactures and distributes nutritional supplements, vitamins, cosmetics, essential oils, and cosmeceuticals for sale across more than 70 countries. The company operates one of the largest production facilities in Europe with a focus on quality control, sustainability, and premium product standards.

1 investor

MaRVis develops MR-safe medical devices, particularly guidewires and catheters, designed to enable MRI-guided minimally invasive surgical procedures in cardiology, oncology, and vascular interventions. The company's proprietary materials allow visualization and safe operation of these devices within MRI environments without radiation exposure.

1 investor